Ernexa Therapeutics Inc (ERNA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2019 | 09-2019 | 06-2019 | 03-2019 | 12-2018 | |
| Sales | 5,168 | 4,580 | 5,226 | 4,832 | 5,919 |
| Cost of Goods | 2,938 | 1,344 | 1,717 | 1,484 | 2,051 |
| Gross Profit | 2,230 | 3,236 | 3,509 | 3,348 | 3,868 |
| Operating Expenses | 4,395 | 3,896 | 4,228 | 4,049 | 3,746 |
| Operating Income | -1,227 | -316 | -2 | -217 | 173 |
| Other Income | -69 | -16 | -88 | -85 | -221 |
| Pre-tax Income | -1,296 | -332 | -90 | -302 | -48 |
| Income Tax | -3 | 19 | 0 | 11 | -100 |
| Net Income Continuous | -1,293 | -351 | -90 | -313 | 52 |
| Net Income | $-1,293 | $-351 | $-90 | $-313 | $52 |
| EPS Basic Total Ops | -6,896.55 | -1,799.10 | -449.78 | -1,649.18 | 449.77 |
| EPS Basic Continuous Ops | -6,736.14 | -1,831.03 | -470.15 | -1,637.35 | 572.92 |
| EPS Diluted Total Ops | -6,896.55 | -1,799.10 | -449.78 | -1,649.18 | 449.77 |
| EPS Diluted Continuous Ops | -6,736.14 | -1,831.03 | -470.15 | -1,637.35 | 572.92 |
| EBITDA(a) | $33 | $547 | $780 | $605 | $1,132 |